An efficient method for the large-scale synthesis of Atorvastatin calcium

Biomolecules and Therapeutics

Volumn 16, Issue 1, 2008, Pages 28-33

  Lee, Hong Woo ^a   Kim, Young Min ^a   Yoo, Choong Leol ^a   Kang, Sung Kwon ^a   Ahn, Soon Kil ^a  

^a Chong Kun Dang Research Institute   (South Korea)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitor; Atorvastatin; Hydrolysis; Large scale synthesis

Indexed keywords

2 [6 [2 [2 (4 FLUOROPHENYL) 5 ISOPROPYL 3 PHENYL 4 (PHENYLCARBAMOYL) 1H PYRROL 1 YL]ETHYL] 2 PHENYL 1,3,2 DIOXABORINAN 4 YL]ACETIC ACID TERT BUTYL ESTER; 5 (4 FLUOROPHENYL) 1 [2 (4 HYDROXY 6 OXOTETRAHYDRO 2H PYRAN 2 YL)ETHYL] 2 ISOPROPYL N, 4 DIPHENYL 1H PYRROLE 3 CARBOXAMIDE; ACETIC ACID DERIVATIVE; AMIDE; ATORVASTATIN; BORONIC ACID DERIVATIVE; LACTONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROLYSIS; INFRARED SPECTROSCOPY; LARGE SCALE PRODUCTION; NUCLEAR MAGNETIC RESONANCE;

EID: 69549121918     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2008.16.1.028     Document Type: Article

References (17)

1. Baumann, K. L., Butler, D. E., Deering, C. F., Mennen, K. E., Millar, A., Nanninga, T. N., Palmer, C. W., and Roth, B. D. (1992). The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33, 2283-2284.
2. Brazil, M. (2002). A new use for statins? Nature Reviews Drug Discovery 1, 934.
3. Brower, P. L., Butler, D. E., Deering, C. F., Le, T. V., Millar, A., Nanninga, T. N., and Roth, B. D. (1992). The synthesis of (4R-cis)-1,1- dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33, 2279-2282.
4. Butler, D. E., Deering, C. F., Millar, A., Nanninga, T. N., and Roth, B. D. (1989). Improved process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran- 2-one inhibitors of cholesterol synthesis. W.O. Patent 89/07598.
5. Butler, D. E., Dejong, R. L., Nelson, J. D., Pamment, M. G., and Stuk, T. L. (2002). Novel Process for the synthesis of 5-(4-Fluorophenyl)-1-[2-((2R,4R)- 4-hydroxy-6-oxo-tetrahydropyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3- carboxylic acid phenylamide. W.O. Patent 02/055519.
6. Graul, A., and Castaner, J. (1997). Atorvastatin calcium. Drugs Future. 22, 956-968.
7. Kathawala, F. G. (1991). HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev. 11, 121-146.
8. Moody, D. J., and Wiffen, J. W. (2005). Process and intermediate compound useful in the preparation of statins, particularly atorvastatin. W.O. Patent 05/012246.
9. 13C NMR and mass spectrometry. J. Am. Chem. Soc. 107, 3694-3701.
10. Park, W. K. C., Kennedy, R. M., Larsen, S. D., Miller, S., Roth, B. D., Song, Y., Steinbaugh, B. A., Sun, K., Tait, B. D., Kowala, M. C., Trivedi, B. K., Auerbach, B., Askew, V., Dillon, L., Hanselman, J. C., Lin, Z., Lu, G. H., Robertson, A., and Sekerke, C. (2008). Hepatoselectivity of statins: Design and synthesis of 4-sulfamoylpyrroles as HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 18, 1151-1156. (Pubitemid 351179323)
11. Roth, B. D., and Mich, A. A. (1987). Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 4,681,893.
12. Roth, B. D., Sliskovic, D. R., and Trivedi, B. K. (1989). Treatment of hypercholesterolemia. Annu. Rep. Med. Chem. 24, 147-156.
13. Roth, B. D., Blankley, C. J., Chucholowski, A. W., Ferguson, E., Hoefle, M. L., Ortwine, D. F., Newton, R. S., Sekerke, C. S., Sliskovic, D. R., Stratton, C. D., and Wilson, M. W. (1991). Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem. 34, 357-366.
14. Roth, B. D., and Mich, A. A. (1993). [R-(R*,R*)]-2-(4- Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof. U.S. Patent 5,273,995.
15. Sattigeri, J. A., Salman, M., Rawat, S., and Sethi, S. (2005). Process for the preparation of atorvastatin. W.O. Patent 05/118536.
16. Srinath, S., Mathew, J., Ujire, S., Sridharan, M., and Sambasivam, G. (2002). Process for the atorvastatin form V and phenylboronates as intermediate compounds. W.O. Patent 02/057274.
17. 13C-enriched substrates to trace impurity generation and removal in the synthesis of atorvastatin. Org. Process. Res. Dev. 1, 320-324.